OncoSense® is a next-generation Superparamagnetic Iron Oxide (Fe3O4) Nanoparticles based MRI Contrast agent and drug delivery vehicle, conjugated with a patent pending tumour targeting peptide. OncoSense® is highly sensitive towards the early stage (sometimes even in the transitional stage)  adenocarcinomas and squamous cell carcinomas. It can also target almost all types of epithelial origin solid tumours at later stages (from Stage II), including pancreatic tumour as OncoSenseⓇ can break thick tumour stroma along with stromal secretions because of its distinct surface modification technique. OncoSenseⓇ is most sensitive to the changes in molecular information rather than anatomic changes, which helps in the early detection of hidden micrometastasis.